Is p16-Positive Good or Bad in Squamous Cell Carcinoma?

In most types of squamous cell carcinoma, testing positive for p16 is associated with better survival, but the strength of that association varies enormously depending on where the cancer is. The clearest benefit appears in oropharyngeal cancers of the throat, where p16 positivity roughly doubles long-term survival compared with p16-negative tumors. In skin-derived squamous cell carcinomas, though, p16 status appears to mean almost nothing for outcomes. The short answer is that p16-positive is usually favorable, but “usually” hides important exceptions that matter for treatment decisions and patient expectations.

What p16 Actually Does in Normal Cells

The p16 protein is a brake on cell division. It works by blocking an enzyme complex that would otherwise push a cell from its resting phase into active DNA replication. When p16 is functioning normally, it can halt cell growth when something goes wrong, giving the cell time to repair damage or self-destruct before becoming cancerous.¹ This makes p16 a classic tumor suppressor: its job is to prevent cancer.

Here’s where the confusion starts. In many cancers, p16 is switched off through chemical modifications to its gene, essentially silencing it. Roughly three-quarters of head and neck squamous cell carcinomas show apparent loss of p16 protein, often through a process called promoter methylation that shuts the gene down without deleting it.² That pattern makes intuitive sense: cancer disables its own brakes. But in HPV-driven cancers, the opposite happens. The virus knocks out a different tumor suppressor called pRb, and the cell responds by flooding itself with p16 in a futile attempt to compensate.³ So when a pathologist sees high p16 staining in a tumor, it often signals that HPV is driving the cancer rather than the usual culprits of tobacco and alcohol.

Oropharyngeal Cancer, Where p16 Matters Most

The strongest and most consistent evidence for p16 as a favorable marker comes from cancers of the oropharynx, the region including the tonsils and the base of the tongue. A systematic review and meta-analysis of eighteen studies found that patients with p16-positive oropharyngeal squamous cell carcinoma had significantly better outcomes across every measure examined, including overall survival, local recurrence, and disease-free survival.⁴

The survival gap is substantial. In one phase III trial, two-year overall survival was about 91% for p16-positive patients compared with 74% for p16-negative patients.⁵ Longer follow-up data show the gap persists: at ten years, about 60% of p16-positive patients were alive compared with roughly 30% of p16-negative patients, and at fifteen years the split was about 57% versus 21%.⁶ These are not marginal differences. For a patient newly diagnosed with oropharyngeal cancer, hearing that their tumor is p16-positive is genuinely meaningful news.

Why p16-Positive Tumors Respond Better to Treatment

Part of the survival advantage comes from the biology of these tumors. Lab studies show that HPV-positive, p16-positive head and neck cancer cells are more sensitive to radiation than their HPV-negative counterparts. The likely reason is that these cells have a harder time repairing DNA damage after radiation exposure, which means more cancer cells die per treatment session.⁷ Additional mechanisms may include differences in how these tumor cells signal for regrowth after treatment and how they move through their division cycle.⁸

This heightened sensitivity to radiation has practical consequences. It raises the question of whether p16-positive patients could be treated with less aggressive regimens and still achieve excellent outcomes while suffering fewer side effects.

De-Escalation Trials and What They Mean for Patients

Because p16-positive oropharyngeal cancers respond so well to standard treatment, researchers have been asking whether they can dial back the intensity. Standard radiation and chemotherapy for head and neck cancer are brutal, causing severe swallowing difficulty, dry mouth, and other long-term problems. If gentler treatment works just as well for this group, the quality-of-life benefits would be enormous.

Early-phase trials have shown promise. In one study, p16-positive patients with limited smoking histories received a reduced radiation dose of 60 Gy with weekly cisplatin. The overall complete response rate was about 86%, with significantly fewer severe side effects than conventional treatment. A subsequent randomized trial of 306 p16-positive patients compared this reduced-dose radiation plus cisplatin against reduced-dose radiation alone. The chemotherapy arm achieved a two-year progression-free survival of about 91%, meeting the trial’s success threshold.⁹

The catch is that phase III trials have not yet confirmed these results reliably enough for de-escalation to become standard practice. A 2024 review concluded that while the phase II data are encouraging, the larger confirmatory trials have not demonstrated clear improvement, and better risk stratification is needed before de-escalated treatment can be recommended outside of clinical trials.¹⁰ One early trial using the EGFR-targeting drug cetuximab as a substitute for standard platinum chemotherapy actually showed worse survival in the HPV-positive group, a cautionary result.¹¹ So for now, p16-positive status is not yet a green light for less treatment. It is a reason for optimism about prognosis, but the standard-of-care protocols remain the default.

How p16 Changed Cancer Staging

The survival difference is so large and so consistent that oncologists decided p16 status needed to be built into the staging system itself. Starting with the 8th edition of the AJCC staging manual, oropharyngeal cancers are now staged differently depending on whether the tumor is p16-positive. A p16-positive tumor and a p16-negative tumor with identical size and spread will receive different stage classifications. In practice, this means many patients who would have been staged as having advanced cancer under the old system are now classified with earlier-stage disease when their tumor is p16-positive.¹²

This split staging is unusual in oncology and reflects how profoundly p16 status reshapes the expected disease course. It also means that when patients compare notes online, a “stage III” p16-positive cancer and a “stage III” p16-negative cancer are fundamentally different diseases with very different expected outcomes.

The Discordance Problem: When p16-Positive Does Not Mean HPV-Positive

One important wrinkle is that p16 positivity and HPV infection do not perfectly overlap. About one in ten p16-positive oropharyngeal tumors turns out to be HPV-negative when tested with more specific molecular methods.¹³ This matters because the survival benefit is concentrated in patients who are both p16-positive and HPV-positive. In a large international analysis, five-year overall survival was about 81% for p16-positive/HPV-positive patients but only about 55% for p16-positive/HPV-negative patients, a gap of roughly 26 percentage points.¹³

Another study estimated that this discordance leads to approximately one excess cancer-related death for every ten p16-positive/HPV-negative patients when compared to truly HPV-driven tumors.¹⁴ While one older study found that p16 positivity alone still predicted better outcomes regardless of HPV testing,¹⁵ the larger and more recent data make a strong case that the discordant group (p16-positive but HPV-negative) does worse than the fully concordant group and should not be assumed to carry the same favorable prognosis.

Why the discordance? p16 can be overexpressed for reasons unrelated to HPV, such as other mutations or cellular stress responses. Because p16 immunohistochemistry is inexpensive and widely available, it is used as a first-line test and performs well as a screening tool, with sensitivity above 96%.¹⁶ But its specificity is not perfect, and combining p16 with a direct HPV test reduces misclassification.¹⁷ Whether that dual-testing approach should become routine is an active area of debate, especially for borderline cases or for enrollment in de-escalation clinical trials.

p16 in Cutaneous Squamous Cell Carcinoma

Squamous cell carcinoma of the skin is a different beast. About a third of cutaneous squamous cell carcinomas of the head and neck show strong p16 staining, and that rate climbs in poorly differentiated tumors. But critically, these skin cancers are not driven by HPV; molecular testing for the virus comes back negative across the board. And p16 status carries no prognostic weight. In one study of 166 cutaneous squamous cell carcinomas, p16 expression was not associated with metastasis, survival, or any meaningful clinical outcome.¹⁸ A second study examining p16-positive lymph node metastases from cutaneous head and neck squamous cell carcinoma confirmed this: p16 status was not prognostic for overall, cancer-specific, or progression-free survival.¹⁹

This has a practical clinical consequence. When a pathologist finds a p16-positive lymph node in the neck, the instinct is to assume an HPV-driven oropharyngeal primary tumor. But in geographic regions where cutaneous squamous cell carcinoma is common, the p16-positive node may have come from a skin cancer instead. Mistaking a skin-origin metastasis for an oropharyngeal primary could send the patient down a very different and potentially wrong diagnostic workup.

Lung, Esophageal, and Vulvar Squamous Cell Carcinomas

Outside the head and neck region, p16’s prognostic role follows a general trend: its presence tends to be favorable, but the evidence is thinner and less definitive than in oropharyngeal cancer.

In lung squamous cell carcinoma, a meta-analysis found that lower p16 expression was associated with worse survival.²⁰ A study of early-stage non-small cell lung cancer confirmed that p16-positive patients had significantly better outcomes than p16-negative patients.²¹ In lung cancer, the mechanism is different from oropharyngeal tumors: p16 expression here likely reflects an intact tumor suppressor pathway rather than an HPV-driven overexpression. The gene is simply doing its job.

In esophageal squamous cell carcinoma, a meta-analysis found that p16 overexpression was significantly associated with better five-year overall survival, earlier tumor stages, and less lymph node involvement.²² A systematic review identified p16 as one of only three immunohistochemical markers reproducibly associated with favorable prognosis in esophageal squamous cell carcinoma.²³ However, at least one study using multivariate analysis found that HPV and p16 status were not independently predictive when other factors were accounted for.²⁴ The overall picture leans favorable but is less definitive than for oropharyngeal cancer.

In vulvar squamous cell carcinoma, p16-positive patients were less likely to experience recurrence and had no cancer-related deaths in one study, suggesting that HPV-driven vulvar cancers represent a less aggressive subtype.²⁵

Beyond the Oropharynx, p16 Still Signals Something

One question patients and clinicians raise is whether p16 matters only for oropharyngeal sites or whether it carries broader prognostic value across head and neck cancers. A large study that examined both oropharyngeal and non-oropharyngeal head and neck cancers found that p16-positive tumors had improved survival at both site types. In non-oropharyngeal primaries, the survival benefit was actually comparable in magnitude, with the risk of dying from cancer cut by more than half in p16-positive cases.²⁶ This finding has not been incorporated into staging systems the way oropharyngeal data have, and the numbers of p16-positive tumors at non-oropharyngeal sites are smaller, but the signal is there.

Smoking Erodes the p16 Advantage

Even within the p16-positive oropharyngeal group, not all patients do equally well. Smoking is the most important modifier. An analysis of two large clinical trials found that the risk of cancer progression and death increased by about 1% per pack-year of smoking history, and this effect was independent of p16 status.²⁷ Another study showed the dose-dependent impact starkly: five-year overall survival among HPV-positive patients dropped from the 90s for never-smokers down to about 59% for those with more than 30 pack-years of smoking history.²⁸ Current smokers at the time of treatment fared worst of all.

Patients with 25 or more pack-years showed a dose-dependent decrease in recurrence-free survival compared with never-smokers, and this effect held up after adjusting for stage and demographics.²⁹ This is why smoking history is one of the key stratification factors in de-escalation trials: a p16-positive tumor in a 40-pack-year smoker is a fundamentally different clinical situation from the same tumor in a never-smoker.

Immunotherapy and the Tumor Microenvironment

Immune checkpoint inhibitors have become part of the treatment landscape for recurrent or metastatic head and neck cancer, but HPV-positive and HPV-negative tumors do not respond uniformly. Single-cell analyses of HPV-positive oropharyngeal tumors have revealed that a specific population of immune cells, called resident memory T cells, can express a marker called CD161 that appears to dampen anti-tumor activity. Patients whose tumors contained high levels of these CD161-expressing T cells had worse responses to immunotherapy, with an inverse correlation between the density of these cells and tumor shrinkage.³⁰

This finding helps explain why even within the favorable p16-positive/HPV-positive group, immunotherapy outcomes are mixed. The tumor microenvironment, specifically the balance of immune cell subtypes and the signals they exchange, can override the generally favorable biology of HPV-driven tumors. Research into targeting CD161 or related pathways to improve immunotherapy responses in this population is ongoing.

The Psychosocial Side of an HPV-Related Diagnosis

Being told your cancer is p16-positive and HPV-related introduces a dimension that other cancer diagnoses do not. Because HPV is sexually transmitted, some patients experience feelings of stigma, embarrassment, or shame. Systematic reviews of the psychosocial impact have found that while most concerns are cancer-related rather than specifically HPV-related, a subset of patients report that the HPV link affected their self-esteem and their intimate relationships.³¹ Some patients described the HPV diagnosis as “the elephant in the room,” withholding information from partners or others because of the sexually transmitted nature of the infection.³²

Healthcare providers do not always address this well. A review noted that clinicians themselves have expressed concerns about how to communicate the HPV link to patients, and patient awareness of the connection between HPV and head and neck cancer remains inconsistent.³³ It is worth noting that HPV is extremely common, most sexually active people are exposed at some point, and the lag between infection and cancer development can be decades. The stigma is real but the biology is not unusual.